Seegene said Wednesday that it has developed the world’s first molecular diagnostic reagent using artificial intelligence (AI).
Using its AI reagent development automation system, the company developed two high multiplex real-time polymerase chain reaction (PCR) reagents that detect meningitis or sexually transmitted diseases. The two reagents can simultaneously detect eight disease-related genes in a single test.
“The company confirmed that the products developed by the AI system had the same efficacy as those developed by professional researchers,” a company official said in a statement. “In the past, experienced and highly educated researchers spent more than a year to develop the products. However, with the new AI system, the company managed to succeed in developing a product in only four days.”
The AI system used in developing the reagents combines the know-how Seegene obtained from its 15 years of experience in developing molecular diagnostic reagent and its patents.
More than 130 experts ranging from biology, biology information, chemistry, statistics, mathematics, physics, electronic engineering, mechanical engineering and computer science participated in developing the AI system.
The company expects to drastically reduce the time spent in developing reagents using the AI system in the future.
“The development of medical devices with artificial intelligence has already surpassed human development,” CEO Chun Jong-yoon said. “The company expects that all future molecular diagnostic reagents will be developed using artificial intelligence.”
By dramatically reducing development costs and time, which was the biggest obstacle to existing molecular diagnostic reagent development, the cost of testing has also decreased, Chun added.
The company plans to pursue “Project 100,” a program aimed to expand its Allpex product lineup to 100 products, by using its AI system. It also plans to obtain the European CE certification for these products.
<© Korea Biomedical Review, All rights reserved.>